BioMed SA eyes new road map to greater economic wins

BioMed SA President Ann Stevens (Photo by Lyndsey Johnson) By W. Scott Bailey, San Antonio Business ...

Diabetes, Infectious Diseases Early Focus of San Antonio Biomed Plan

David Holley, Xconomy Texas —  San Antonio — [Updated 12/14/17, 11:54 p.m. See below.] ...

Industry Publications

The Mission

The Mission is published by the University of Texas Health Science Center.

UTSA Discovery

UTSA Discovery is published annually for the Office of the Vice President for Research by the Office ...


April 10, 2017

Time5:00 PM Reception, 5:30 Lecture

Location: UTSA Main 1604 Campus, UC Ballroom I

Parking:  Free

Subject:  Parkinson’s disease is the second most common neurodegenerative disorder in the U.S.  There are no proven strategies for preventing it or slowing its progression. But there is hope that new treatment is on the horizon.  This talk will outline the rationale for a large Phase 3 clinical neuroprotection trial in early stage Parkinson’s disease with the drug isradipine that is being sponsored by the National Institutes of Health. 

Speaker: James Surmeier, PhD, is the Nathan Smith Davis Professor and Chair, Department of Physiology at Feinberg School of Medicine at Northwestern University.  He is a leading authority on the fundamental mechanisms of Parkinson’s disease and directs the Morris K. Udall Center of Excellence for Parkinson’s Disease at Northwestern – one of nine elite, multi-disciplinary centers funded by the National Institutes of Health focused on causes and cures for Parkinson’s Disease.

For more details, see:


Stay informed. Subscribe to BioMed SA news alerts.